Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim
A Phase 2 Interventional Single Arm Study Describing Platelet Responses and ITP Remission Rates in Adult Subjects With Immune Thrombocytopenia Purpura Receiving Romiplostim
Sponsor: Amgen
Listed as NCT01143038, this PHASE2 trial focuses on Idiopathic Thrombocytopenic Purpura and remains completed. Sponsored by Amgen, it has been updated 10 times since 2010, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Sep 2022 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
Jun 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Sep 2018 — Jun 2019 [monthly]
Completed PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Nov 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Adelaide, Australia , Alcorcón, Spain , Anaheim, United States , Barcelona, Spain , Bari, Italy , Bethesda, United States , Bondy, France , Boynton Beach, United States , Brno, Czechia and 35 more locations